NEW YORK (GenomeWeb News) – The Ontario Genomics Institute said today that it has provided funding to Tissue Regeneration Therapeutics (TRT), a company developing umbilical stem cell-based treatments for a range of diseases, that will support 'omics-based research projects.
OGI and the company did not disclose the amount of the investment. The funds will support proteomic and transcriptomic analyses that will provide information the firm will need to gain the regulatory approval to conduct human clinical trials and to differentiate their product from competitors.
OGI provided the investment through its Pre-Commercialization Business Development Fund, which invests in genomics, proteomics, and associated technologies that are in the proof-of-principle phase.
Toronto-based TRT's technology seeks to use umbilical mesenchymal stem cells to treat conditions such as arthritis, diabetes, and Crohn's disease, among others, and it hopes to launch clinical trials within two years.